19 March 2025 UK biotech Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (I-O) and antibody drug conjugate (ADC)-based therapies, today announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback